|Day Low/High||42.76 / 44.34|
|52 Wk Low/High||31.25 / 58.46|
Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.
Here are Friday's top research calls, including upgrades for Ford, Intel and Wynn Resorts, and a downgrade for Whirlpool.
The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.
Eight Week Study Assessed Safety, Tolerability and Efficacy in 124 Adult Subjects
Company to Host Conference Call and Webcast Today, January 5th at 4:30pm ET / 1:30pm PT
Live Audio Webcast will be on January 9, 2017
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Will Continue to Support Company Over Extended Transition Period Through End of 2017
Live Audio Webcast will be on December 14, 2016
New One Year Safety and Efficacy Data of INGREZZA in Tardive Dyskinesia Patients
Advisory Committee Meeting Scheduled for February 16, 2017
Live Audio Webcast will be on November 30, 2016
Live Audio Webcast will be on November 16, 2016
Live Audio Webcast will be on November 7, 2016
Conference Call and Webcast Scheduled For Wednesday, November 2, 2016
- Elagolix shows superiority compared to placebo in reducing daily menstrual and non-menstrual pelvic pain associated with endometriosis
The squeeze is on these stocks, and they are poised for volatile moves.
Live Audio Webcast will be on September 13, 2016
Live Audio Webcast will be on September 7, 2016
Six Month Open Label Safety and Tolerability Study of Valbenazine
The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 606,250 share increase in total short interest for Neurocrine Biosciences, Inc. , to 4,930,434, an increase of 14.02% since 06/30/2016.
Conference Call and Webcast Scheduled For Wednesday, August 3, 2016
NBIX, ZPIN, VLP, NWLI and INFO were all recently downgraded by TheStreet's Quant Ratings.